Screw DMOAD. IMO it is a rabbit hole that, if it remains our focus, will just continue to delay registration.
Significant pain reduction and functional improvement with such small sample sizes is OUTSTANDING news.
I'm loving the focus in the headline on pain (rather than DMOAD). I'm also loving the focus on a specific dose. They are signalling clarity regarding approach to FDA, which is very welcome.
Well done to them.
Ann: iPPS SIGNIFICANT OA PAIN REDUCTION AT 12 MONTHS, page-15
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.010(5.13%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.0¢ | 20.0¢ | $206.0K | 1.009M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 217901 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 57971 | 5 |
View Market Depth
| Last trade - 15.09pm 10/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |